Promising new imaging probes could spot prostate cancer missed by standard scans
NCT ID NCT07363382
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two new imaging agents (68Ga-G21 and 68Ga-G23) that target a protein found on most prostate cancer cells. The goal is to see if these PET scans can find cancers that standard PSMA scans might miss, helping doctors better stage the disease and guide treatment. Six adults with prostate cancer will receive both the new and standard scans for comparison.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER (ADENOCARCINOMA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University
RECRUITINGFuzhou, Fujian, 350005, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A sharper eye on prostate cancer: could new imaging spare healthy tissue?
- Can a new drug combo tame resistant prostate cancer?
- Virtual cooking classes aim to boost health for hispanic prostate cancer survivors and their families
- Prostate Surgery's hidden toll: study probes lasting impact on Men's lives
- Which gas pump causes less pain during robotic prostate surgery? a Head-to-Head trial
- Nerve-Sparing radiation may help men keep sexual function after prostate cancer treatment